MP-ORIF will have a significant impact on various levels:
Market/clients (hospitals, healthcare providers, doctors): shorter surgery time and higher success rate than current surgeries as there is no need for additional corrective surgeries and the nail may stay in the body for lifetime.
Hence, this represents 50 % lower overall cost for the hospital and healthcare providers (Section 4.7) on one side as well as a better reputation and increased visibility for the hospitals and the doctors on the other side.
In addition, the doctors and the medical staff are exposed to less X-ray imaging.

Thus, trauma surgeries can be also offered by small and medium hospitals and private clinics that can’t serve congestions in large hospitals.
Simplification of the intraoperative equipment will reduce not only the cost per intervention but also the cost associated to the necessary training of an orthopaedic surgeon.
End-user (patients): shorter post-operation recovery time → patients are more active earlier, with greatly reduced scarring.
Using MP-1TM nails instead of metal ones will eliminate pain as a result of much lower heat conductivity compared to metal.
The patient quality of life will be significantly improved by the drastic elimination of lifelong adverse effects experienced after surgery and the fact that there is no need for an additional surgery after healing since the implant can stay in the body for lifetime without risk or discomfort.

Company: an increase in MMATECH’s revenue in the first 5 years after launch of selling MP-ORIF.
By the 5th commercialization year we will have 8.9 M€ revenue and 16 new employees.
Stakeholders: The reduced need for repetitive X-ray imaging, decrease in number of control visits, shorter hospitalization, no need for additional surgeries, and the necessary analgesics prescription will lower the public healthcare costs and contribute to meliorating the austerity European situation
Society: developing economies may gain access to high quality trauma care otherwise impossible.
Women will be the major beneficiaries of MP-ORIF project (Section 1.3)


We declare that our new polymeric material can withstand the natural properties required by the joint and may last in the body at least 25-30 years (Figure 10).
The material chosen for an implant should withstand different load modes (tensile, compression and shear) and resist friction and wear.
The debris created in hip simulator (5M cycles) were analysed and were all larger than 5 µm, a size which can't be swallowed by macrophages thus not causing inflammation.

ntellectual property and knowledge protection

Device manufacturers use high-performance polymers in a variety of orthopaedic and spinal implants such as lumbar and cervical spacers.
Many of the screws and rods for spinal implants are also produced from polymers22.
MMATECH holds Patent USP 6686437 covering all medical applications of the MP-1TM material.
Material composition of the MP-1TM is covered by a trade secret which has been developed by an outsourced manufacturer (Imitec) in the US for non-medical applications.
A spin-off of this material was developed for medical use.
We received exclusive rights from the manufacturer for all medical applications.
We used PATENTSCOPE with over 56 million records in order to look for the international patent applications and regional and national patent collections.
After an exhaustive search we found 5 patents of interest.
None of the patents have the combination of having the biocompatible material and tailor made solution for a specific bone (such as small femoral bone).
An additional search revealed 4 patents of interest.
In general, over 100 patents resulted from the search, but the patents of interest were coming from mostly 2 applicants: NANO ORTHOPEDICS and NEOS SURGERY.

IPR strategy

Based on the results of the search conducted we have freedom to operate.
We will create a new implant design which must be protected. The kind of protection will be by patent.
We will therefore keep the design of MP-ORIF confidential until a patent will be applied in T6.2. First meetings with a patent lawyer were already done concerning the patent draft.
They will continue during the Phase 2 period.
Their costs, including the application fees, are included in the project budget plan.
We have performed a throughout patentability analysis to ensure our new implant technology will be patentable.
The results allow the new MP-ORIF implant technology to be patented in target countries (USA, EU).
There are no infringements of third party patents.
We will also register the trademark for the MP-ORIF’ s name and its logo in the countries where MP-ORIF will be sold.
We will be the sole proprietors from the results that the subcontractors provide us.
Also, we reserve the exclusive right to publish any results that the subcontractors come up with as part of the subcontracted tasks.
Any subcontractor will be informed on these statements and will provide us with a written consent on them.
We will also insert a section in the MMATECH’s homepage dedicated specifically for the purpose of presenting the product and the market, the selling opportunities together with all the necessary contacts (see also T7.3 and D7.1).